Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-19T05:03:10.876Z Has data issue: false hasContentIssue false
  • English
  • Français

Hepatocellular carcinoma in the adult Fontan patient

Published online by Cambridge University Press:  19 September 2016

Michael R. Conroy Open the ORCID record for Michael R. Conroy [Opens in a new window]  and
Tabitha G. Moe
Michael R. Conroy
Affiliation:
Department of Cardiology, Mayo Clinic, Scottsdale, Arizona, United States of America
Tabitha G. Moe*
Affiliation:
Department of Cardiology, Mayo Clinic, Scottsdale, Arizona, United States of America
*
Correspondence to: Dr T. Moe, Department of Cardiology, Mayo Clinic, Scottsdale, AZ 85054, United States of America. Tel: 480 515 6296; Fax: 602 933 4166; E-mail: Moe.tabitha@mayo.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

In this study, we describe the case of a 36-year-old woman who was diagnosed with hepatocellular carcinoma on a background of Fontan procedure for tricuspid atresia. She had worsening heart failure in the months before presentation, and early investigations noted derangement in liver enzymes and hepatomegaly. Liver biopsy confirmed a hepatocellular carcinoma. Hepatocellular carcinoma is a rare but recognised consequence of cardiac cirrhosis in Fontan patients.

Keywords

Fontanhepatocellularcirrhosisscreening
Type
Brief Report
Information
Cardiology in the Young , Volume 27 , Issue 2 , March 2017 , pp. 407 - 409
Check for updates
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Ho, SS, Brown, R, Fitzgibbon, B. Hepatocellular carcinoma with cardiac cirrhosis. Med J Aust 1990; 152: 553–554.Google Scholar
2. Ghaferi, AA, Hutchins, GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 2005; 129: 1348–1352.Google Scholar
3. Ottenkamp, J, Rohmer, J, Quaegebeur, JM, et al. Nine years’ experience of physiological correction of tricuspid atresia: long-term results and current surgical approach. Thorax 1982; 37: 718–726.Google Scholar
4. Lemmer, JH, Coran, AG, Behrendt, DM, et al. Liver fibrosis (cardiac cirrhosis) five years after modified Fontan operation for tricuspid atresia. J Thorac Cardiovasc Surg 1983; 86: 757–760.Google Scholar
5. Bruix, J, Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.Google Scholar
6. Asrani, SK, Warnes, CA, Kamath, PS, et al. Hepatocellular carcinoma after the Fontan procedure. N Eng J Med 2013; 368: 1756–1757.CrossRefGoogle ScholarPubMed
7. Josephus Jitta, D, Wagenaar, LJ, Mulder, BJM, et al. Three cases of hepatocellular carcinoma in Fontan patients: review of the literature and suggestions for hepatic screening. Int J Cardiol 2016; 206: 21–26.Google Scholar
8. Assenza, GE, Graham, DA, Landzberg, MJ, et al. MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery. Heart 2013; 99: 491–496.CrossRefGoogle ScholarPubMed
9. Elder, RW, McCabe, NM, Hebson, C, et al. Features of portal hypertension are associated with major adverse events in Fontan patients: The VAST study. Int J Cardiol 2013; 168: 3764–3769.Google Scholar